Discovery of CX-6258. A potent, selective, and orally efficacious pan-pim kinases inhibitor

ACS Medicinal Chemistry Letters

Volumn 3, Issue 2, 2012, Pages 135-139

  Haddach, Mustapha ^a   Michaux, Jerome ^a   Schwaebe, Michael K ^a   Pierre, Fabrice ^a   O'Brien, Sean E ^a   Borsan, Cosmin ^a   Tran, Joe ^a   Raffaele, Nicholas ^a   Ravula, Suchitra ^a   Drygin, Denis ^a   Siddiqui Jain, Adam ^a   Darjania, Levan ^a   Stansfield, Ryan ^a   Proffitt, Chris ^a   MacAlino, Diwata ^a   Streiner, Nicole ^a   Bliesath, Joshua ^a   Omori, May ^a   Whitten, Jeffrey P ^a   Anderes, Kenna ^a   Rice, William G ^a   Ryckman, David M ^a   more..

^a Cylene Pharmaceuticals   (United States)

Author keywords

CX 6258; MV 4 11; PC3; Pim 1; Pim 2; Pim 3

Indexed keywords

ANTINEOPLASTIC AGENT; CX 6258; DOXORUBICIN; PACLITAXEL; PIM KINASE; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

EID: 84856853371     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml200259q     Document Type: Article

References (35)

1. Nawijn, M. C.; Alendar, A.; Berns, A. For better or for worse: the role of Pim oncogenes in tumorigenesis Nat. Rev. Cancer 2010, 11, 23-34
2. Amaravadi, R.; Thompson, C. B. The survival kinases Akt and Pim as potential pharmacological targets J. Clin. Invest. 2005, 115 (10) 2618-24 (Pubitemid 41434384)
3. Eichmann, A.; Yuan, L.; Breant, C.; Alitalo, K.; Koskinen, P. J. Developmental expression of pim kinases suggests functions also outside of the hematopoietic system Oncogene 2000, 19 (9) 1215-24 (Pubitemid 30157552)
4. Allen, J. D.; Verhoeven, E.; Domen, J.; van der Valk, M.; Berns, A. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc Oncogene 1997, 15 (10) 1133-41 (Pubitemid 27429616)
5. Yip-Schneider, M. T.; Horie, M.; Broxmeyer, H. E. Transcriptional induction of pim-1 protein kinase gene expression by interferon gamma and posttranscriptional effects on costimulation with steel factor Blood 1995, 85 (12) 3494-502
6. Bachmann, M.; Moroy, T. The serine/threonine kinase Pim-1 Int. J. Biochem. Cell Biol. 2005, 37 (4) 726-30 (Pubitemid 40202995)
7. Zhang, Y.; Wang, Z.; Li, X.; Magnuson, N. S. Pim kinase-dependent inhibition of c-Myc degradation Oncogene 2008, 27 (35) 4809-19
8. Ellwood-Yen, K.; Graeber, T. G.; Wongvipat, J.; Iruela-Arispe, M. L.; Zhang, J.; Matusik, R.; Thomas, G. V.; Sawyers, C. L. Myc-driven murine prostate cancer shares molecular features with human prostate tumors Cancer Cell 2003, 4 (3) 223-38 (Pubitemid 37163836)
9. Moroy, T.; Verbeek, S.; Ma, A.; Achacoso, P.; Berns, A.; Alt, F. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice Oncogene 1991, 6 (11) 1941-8 (Pubitemid 21924031)
10. Aho, T. L.; Sandholm, J.; Peltola, K. J.; Mankonen, H. P.; Lilly, M.; Koskinen, P. J. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site FEBS Lett. 2004, 571 (1-3) 43-9 (Pubitemid 38992921)
11. Macdonald, A.; Campbell, D. G.; Toth, R.; McLauchlan, H.; Hastie, C. J.; Arthur, J. S. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL BMC Cell Biol. 2006, 7, 1
12. Yan, B.; Zemskova, M.; Holder, S.; Chin, V.; Kraft, A.; Koskinen, P. J.; Lilly, M. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death J. Biol. Chem. 2003, 278 (46) 45358-67 (Pubitemid 37432672)
13. Selten, G.; Cuypers, H. T.; Berns, A. Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas EMBO J. 1985, 4 (7) 1793-8
14. Li, Y. Y.; Popivanova, B. K.; Nagai, Y.; Ishikura, H.; Fujii, C.; Mukaida, N. Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines Cancer Res. 2006, 66 (13) 6741-7 (Pubitemid 44085632)
15. Wang, Z.; Bhattacharya, N.; Mixter, P. F.; Wei, W.; Sedivy, J.; Magnuson, N. S. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase Biochim. Biophys. Acta 2002, 1593 (1) 45-55 (Pubitemid 35335911)
16. Mochizuki, T.; Kitanaka, C.; Noguchi, K.; Muramatsu, T.; Asai, A.; Kuchino, Y. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway J. Biol. Chem. 1999, 274 (26) 18659-66
17. Morishita, D.; Katayama, R.; Sekimizu, K.; Tsuruo, T.; Fujita, N. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels Cancer Res. 2008, 68 (13) 5076-85
18. Bachmann, M.; Kosan, C.; Xing, P. X.; Montenarh, M.; Hoffmann, I.; Moroy, T. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C Int. J. Biochem. Cell Biol. 2006, 38 (3) 430-43 (Pubitemid 41821890)
19. Dhanasekaran, S. M.; Barrette, T. R.; Ghosh, D.; Shah, R.; Varambally, S.; Kurachi, K.; Pienta, K. J.; Rubin, M. A.; Chinnaiyan, A. M. Delineation of prognostic biomarkers in prostate cancer Nature 2001, 412 (6849) 822-6 (Pubitemid 32801464)
20. Morwick, T. Pim kinase inhibitors: a survey of the patent literature Expert Opin. Ther. Pat. 2010, 2, 193-212
21. Ren, J. X.; Li, L. L.; Zheng, R. L.; Xie, H. Z.; Cao, Z. X.; Feng, S.; Pan, Y. L.; Chen, X.; Wei, Y. Q.; Yang, S. Y. Discovery of novel Pim-1 kinase inhibitors by a hierarchical multistage virtual screening approach based on SVM model, pharmacophore, and molecular docking J. Chem. Inf. Model. 2011, 51 (6) 1364-75
22. Xiang, Y.; Hirth, B.; Asmussen, G.; Biemann, H. P.; Bishop, K. A.; Good, A.; Fitzgerald, M.; Gladysheva, T.; Jain, A.; Jancsics, K.; Liu, J.; Metz, M.; Papoulis, A.; Skerlj, R.; Stepp, J. D.; Wei, R. R. The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 3050-6
23. Pierce, A. C.; Jacobs, M.; Stuver-Moody, C. Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase J. Med. Chem. 2008, 51 (6) 1972-5 (Pubitemid 351438879)
24. Pogacic, V.; Bullock, A. N.; Fedorov, O.; Filippakopoulos, P.; Gasser, C.; Biondi, A.; Meyer-Monard, S.; Knapp, S.; Schwaller, J. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity Cancer Res. 2007, 67 (14) 6916-24 (Pubitemid 47105539)
25. Grey, R.; Pierce, A. C.; Bemis, G. W.; Jacobs, M. D.; Moody, C. S.; Jajoo, R.; Mohal, N.; Green, J. Structure-based design of 3-aryl-6-amino- triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase Bioorg. Med. Chem. Lett. 2009, 19 (11) 3019-22
26. Bullock, A. N.; Debreczeni, J. E.; Fedorov, O. Y.; Nelson, A.; Marsden, B. D.; Knapp, S. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase J. Med. Chem. 2005, 48 (24) 7604-14 (Pubitemid 41698801)
27. Holder, S.; Zemskova, M.; Zhang, C.; Tabrizizad, M.; Bremer, R.; Neidigh, J. W.; Lilly, M. B. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase Mol. Cancer Ther. 2007, 6 (1) 163-72 (Pubitemid 46206679)
28. Cheney, I. W.; Yan, S.; Appleby, T.; Walker, H.; Vo, T.; Yao, N.; Hamatake, R.; Hong, Z.; Wu, J. Z. Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase Bioorg. Med. Chem. Lett. 2007, 17 (6) 1679-83 (Pubitemid 46274341)
29. Tao, Z. F.; Hasvold, L. A.; Leverson, J. D.; Han, E. K.; Guan, R.; Johnson, E. F.; Stoll, V. S.; Stewart, K. D.; Stamper, G.; Soni, N.; Bouska, J. J.; Luo, Y.; Sowin, T. J.; Lin, N. H.; Giranda, V. S.; Rosenberg, S. H.; Penning, T. D. Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases J. Med. Chem. 2009, 52 (21) 6621-36
30. Nishiguchi, G. A.; Atallah, G.; Bellamacina, C.; Burger, M. T.; Ding, Y.; Feucht, P. H.; Garcia, P. D.; Han, W.; Klivansky, L.; Lindvall, M. Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases Bioorg. Med. Chem. Lett. 2011, 21, 6366-9
31. Sun, L.; Tran, N.; Tang, F.; App, H.; Hirth, P.; McMahon, G.; Tang, C. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases J. Med. Chem. 1998, 41 (14) 2588-603 (Pubitemid 28321908)
32. Kim, K. T.; Levis, M.; Small, D. Constitutively activated FLT3 phosphorylates BAD partially through pim-1 Br. J. Hamaetol. 2006, 134 (5) 500-9 (Pubitemid 44141716)
33. Kim, K. T.; Baird, K.; Ahn, J. Y.; Meltzer, P.; Lilly, M.; Levis, M.; Small, D. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival Blood 2005, 105 (4) 1759-67 (Pubitemid 40223700)
34. Zheng, H. C.; Tsuneyama, K.; Takahashi, H.; Miwa, S.; Sugiyama, T.; Popivanova, B. K.; Fujii, C.; Nomoto, K.; Mukaida, N.; Takano, Y. Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression J. Cancer Res. Clin. Oncol. 2008, 134 (4) 481-8 (Pubitemid 351322384)
35. Popivanova, B. K.; Li, Y. Y.; Zheng, H.; Omura, K.; Fujii, C.; Tsuneyama, K.; Mukaida, N. Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis Cancer Sci. 2007, 98 (3) 321-8 (Pubitemid 46195601)